Press release archive

The First SciBX Summit on Innovation in Drug Discovery & Development

PRESS RELEASE FROM NATURE PUBLISHING GROUP
21 August 2012

Contact: Rachel Scheer
Nature Publishing Group
T: +1 212 451 8569
E: **r.scheer@us.nature.com**

Contact: Thomas Carey
BioCentury Publications, Inc.
T: +1-650-595-5333
E: **tcarey@biocentury.com**

REDWOOD CITY, Calif., and NEW YORK, N.Y., August 21, 2012 — BioCentury Publications, Inc., a source of biopharma business intelligence, and Nature Publishing Group (NPG), today announce the inaugural SciBX Summit on Innovation in Drug Discovery & Development.

This unique Think Tank, held in conjunction with EBD Group's BioPharma America™ meeting in Boston on September 21, 2012, will bring together key opinion leaders from academia, biotech, pharma and the investment community to build a roadmap for macrocycles and constrained peptides, which promise to reach therapeutic targets that have been inaccessible to existing drugs and biologics.

NPG and BioCentury, the co-publishers of *SciBX: Science-Business eXchange*, are convening a *SciBX* Think Tank of global leaders in the field: Bruce Booth, Partner at Atlas Venture; Spiros Liras, Head of Medicinal Chemistry in Cardiovascular, Metabolic and Endocrine Diseases at Pfizer Inc. (NYSE:PFE); Barry Morgan, Vice President of Molecular Discovery Research at GlaxoSmithKline plc (NYSE:GSK); Patrick Reid, Co-founder and Chief Scientific Officer , Head of Research & Development of PeptiDream Inc.; Tomi Sawyer, Chief Scientific Officer, SVP Drug Discovery & Innovative Technologies of Aileron Therapeutics Inc.; and Professor Gregory Verdine of Harvard Medical School and Third Rock Ventures.

The *SciBX* Think Tank will convene before the meeting to identify the essential next steps for translating these promising compounds into medicines for patients. The panel's final strategy recommendations will be presented to the *SciBX* Summit, along with presentations on the landscape, challenges and opportunities for this important technology.

The *SciBX* Summit findings will be published in a future edition of *SciBX: Science Business eXchange*. This journal was created in 2008 to marry the scientific acumen of NPG with the business intelligence of BioCentury.

"The vision for *SciBX* is to identify the most commercially promising science and assess the next steps required to develop this new technology," said BioCentury Chairman Karen Bernstein, Ph.D. "The *SciBX* Summit Series advances this vision. It is the first forum to bring key life science stakeholders together with the goal of producing a lasting document identifying the work that must be done to fulfill the promise offered by dynamic and emerging fields of drug development."

"The aim of these summits is to enlist the energy of everyone who wants to create successful innovation in the life sciences," said Gaspar Taroncher-Oldenburg, Ph.D., Managing Editor and Associate Publisher of *SciBX*. "The focus of this first *SciBX* Summit — macrocycles and constrained peptides — is a perfect example of such a sweet spot in innovation where we expect the frank and in-depth discussion within the Think Tank, and at the event itself, will lead to the formulation of a roadmap for true value creation."

"The innovative approach of the *SciBX* Summit is reflected by its Gold Sponsors — Aileron Therapeutics Inc.; Amgen Inc. (NASDAQ:AMGN); BioDuro/PPD Inc.; Ipsen Group (Euronext:IPN), PeptiDream Inc., Sofinnova Ventures and Takeda Pharmaceuticals International, Inc.," said NPG Publishing Director Peter Collins. "We appreciate their generous support for this inaugural event and such has been the response from the community that we are already beginning to plan a larger *SciBX* Innovation Summit for 2013, and annually thereafter."

About Macrocycles & Small Peptides

Molecules in the 500-5,000 Da size have burst onto the drug discovery stage as a way to bridge the gap between small molecules and biologics. The hope is that these molecular entities will combine the pharmacological properties of small molecules with the specificity of biologics to address intracellular protein-protein interactions that have previously been considered undruggable.

The commercial landscape has been heating up, with a number of startups receiving substantial funding, and several biopharmas partnering with startups or initiating their own discovery programs in the space.

How to Attend the *SciBX* Summit

The *SciBX* Summit will take place starting at 9 a.m. on Friday, Sept. 21, at the Boston Westin Waterfront Hotel in conjunction with BioPharm America. The Summit is open to all registered participants at BioPharm America was well as attendees who register at the *SciBX* Summit website, **http://www.nature.com/natureconferences/sidds/index.html.**

-ENDS-

About BioPharm America

Now in its 5th year, EBD Group's BioPharm America partnering meeting will convene at the Boston Westin Waterfront from Sept. 19-21. For more information, visit: **www.ebdgroup.com/bpa/index.php**.

About BioCentury

Now in its 20th year, BioCentury Publications, Inc. provides essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators and public policy makers, and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia.

BioCentury's titles include the flagship *BioCentury®, the Bernstein Report on BioBusiness*; its *SciBX: Science-Business eXchange*™ translational science partnership with Nature Publishing Group; and its *BioCentury Extra*™ online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence™, an online business intelligence resource. BioCentury also produces its *BioCentury This Week* biotech public affairs television program in partnership with the Gannett-owned WUSA9 CBS affiliate in Washington, D.C. The program is aired in Washington each Sunday as part of the WUSA9 "Sunday Morning Power Block," and distributed globally online at www.biocenturytv.com.

For more information, visit **www.biocentury.com** and **www.biocenturytv.com**.

About Nature Publishing Group (NPG)

Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases and services across the life, physical, chemical and applied sciences and clinical medicine.

Focusing on the needs of scientists, *Nature* (founded in 1869) is the leading weekly, international scientific journal. In addition, for this audience, NPG publishes a range of *Nature* research journals and *Nature Reviews* journals, plus a range of prestigious academic journals including society-owned publications. Online, nature.com provides over 6 million visitors per month with access to NPG publications and online databases and services, including news and comment from *Nature*, *Naturejobs* plus access to *Nature Network* and Nature Education's Scitable.com.

Scientific American is at the heart of NPG's consumer media division, meeting the needs of the general public. Founded in 1845, *Scientific American* is the oldest continuously published magazine in the US and the leading authoritative publication for science in the general media. Together with scientificamerican.com and 14 local language editions around the world it reaches over 5 million consumers and scientists. Other titles include *Scientific American Mind* and *Spektrum der Wissenschaft* in Germany.

Throughout all its businesses NPG is dedicated to serving the scientific and medical communities and the wider scientifically interested general public. Part of Macmillan Publishers Limited, NPG is a global company with principal offices in London, New York and Tokyo, and offices in cities worldwide including Boston, San Francisco, Washington DC, Buenos Aires, Mexico City, Sao Paulo, Cairo, Dubai, Delhi, Mumbai, Hong Kong, Shanghai, Melbourne, Osaka, Seoul, Barcelona, Madrid, Basingstoke, Heidelberg, Munich and Paris. For more information, please go to **www.nature.com**.

About us
Contact us
Accessibility statement
Help
Privacy policy
Use of cookies
Legal notice
Terms
Naturejobs
Nature Asia
Nature Education
RSS web feeds

Search: go

SPRINGER NATURE

© 2019 Nature is part of Springer Nature. All Rights Reserved.

partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef, COUNTER and COPE